CHD6 is a chromatin remodeling protein characterized to play a role in transcriptional repression of genes and viruses. It occurs in a nuclear location as a component of a larger complex which associates with RNA Pol II. Mutations in CHD6 are associated with motor coordination defects, and development of cancers following substitutions and translocations.
CHD6 protein functional domains. Chromodomains are highlighted in purple, the highly conserved SNF2-like ATPase region is indicated in light blue, and the DNA binding domain (green oval) contains BRK binding sights, indicated by the red diamonds.
Protein

Description
CHD6 is a member of the very homologous SNF2 superfamily of chromatin remodeling enzymes (SWI2/SNF2, ISWI, and CHD enzyme families). These enzymes all contain a highly conserved HELICc DEAD-like helicase/ATPase with seven conserved catalytic regions (Brown et al., 2007; Marfella and Imbalzano, 2007) . The nine CHD family members all contain nterminal chromodomains and the HELICc ATPase/helicase region, and are split into three subfamilies, distinguished by the additional functional domains in each (Marfella and Imbalzano, 2007; Stanley et al., 2013) . CHD6 contains a DNA binding region in its c-terminal region with conserved BRK domains (Schuster and Stöger, 2002) . CHD6 is localized to the nucleus and is found in large multi-protein chromatin remodeling complexes, including the Nrf2 transcription factor (Nioi et al., 2005) . Additionally, CHD6 is a DNA dependent ATPase. CHD6 protein is expected to function as a transcriptional repressor and it has been shown to be interact with RNA Pol II proteins (Lutz et al., 2006) and to be involved in the cellular repression of viral replication (Fertey et al., 2010; Alfonso et al., 2011; Alfonso et al., 2013 
Localisation
Nuclear.
Function
Chromatin remodeling, transcription co-factor binding, suppression of gene expression.
Homology
CHD6 has homologues in chimpanzee, Rhesus monkey, dog, cow, mouse, rat, chicken, zebrafish, and frog.
Mutations
Note
There have been no reports of naturally occurring homozygous inactivation of CHD6. Mutations have been identified in several types of cancer, however, no nonsense or frameshift mutations exclusive to CHD6 have been associated with cancer to date (Cosmic database). Haploinsufficiency in CHD6 has been reported in miscarriage and mental retardation (Yamada et al., 2010) and mutation of the ATPase region in mice resulted in an ataxia phenotype (Lathrop et al., 2010) .
Implicated in
Acute myeloid leukemia (AML)
Note
The presence of a fusion gene between LMBRD1 and CHD6 was identified in a case report of AML. Development of AML from an acute MDS/MPD diagnosis occurred over two years. FISH mapping of increasingly specific bacterial artificial chromosomes was used to identify the breakpoints of this AML between exons 1 and 2 of CHD6 (DouetGuilbert et al., 2014) . Hybrid/Mutated gene Fusion gene between LMBRD1-CHD6 (6;20)(q13;q12).
Myeloproliferative disorder (MPD)/ myelodysplastic syndrome (MDS)
Note Chromosome 20q12 is a common breakpoint associated with the development of MPD/MDS, however with the increased specificity of chromosome mapping techniques the frequency of the CHD6 gene specifically mutated in this disease is still being more precisely determined (Huh et al., 2010; Padhi et al., 2013) .
Colorectal cancer
Note CHD6 has been implicated in two studies using CHD6 (chromodomain helicase DNA binding protein 6) Lathrop M, et al. Atlas Genet Cytogenet Oncol Haematol. 2015; 19(6) genome wide analysis of colorectal cancer cell lines. A comparison between tumor cell lines and primary tumors found that cell lines accurately reflect the diversity of mutations associated with primary tumor samples (Mouradov et al., 2014) . Additionally this study determined that mutations in chromatin state regulators (including CHD6) are commonly found in colorectal cancer. Further research examined the copy number variation (CNV) found between colorectal cancer and normal tissue samples (Ali Hassan et al., 2014) . Significant alterations in CNV were observed on chromosomes 8, 13, and 20. The gain of copies on chromosome 20q12 was the most significant finding, occurring in 45% of tumor tissues examined, specifically over a 2445 kbp region containing eight genes that include PTPRT, TOP1, and CHD6 (Ali Hassan et al., 2014) .
Bladder transitional cell carcinoma (TCC)
Note Analysis of multiple TCC tissues identified a group of chromatin remodeling enzyme genes with mutations occurring in 59% of patients. CHD6 was found mutated in multiple lines examined, however, only in one line was the mutation exclusive to CHD6. Linked mutation of CHD6 and two other genes, ANK2 or LRP2 was found to correlate with the development of TCC (Gui et al., 2011) .
Various cancers (malignant melanoma, glioma, cervical cancer, lung, urinary tract, large intestine, and others) Note Whole genome analysis of tumor tissues and culture cell lines have identified point mutations within CHD6. These mutations and copy number variations occur at low frequencies and are often not likely pathologically associated with the development of the cancers. The alterations have been found in the following tissues: malignant melanoma (5 substitution mutations: NCBI ClinVar Database, last update 04-24-2014), multiple tumor tissue sources identifying 283 mutations in haematopoietic and lymphoid (0.23% of tested samples), central nervous system (0.74%), cervix (14.3%), endometrium (8.5%), prostate, urinary tract (14.3%), ovary, breast, lung (7.0%), stomach (6.4%), skin, kidney, large intestine (10.6%), liver, oesophagus, and pancreas. The bulk of mutations are composed of nonsense substitution: 7.42%, missense substitution: 68.90%, synonymous substitution: 27.92%, deletion frameshift: 2.12% (COSMIC Database, v69) . This database further identified copynumber variants in the following tissues; haematopoietic and lymphoid, central nervous system, breast, lung, endometrium, kidney, large intestine, lung, ovary, and pancreas tumor tissues, with gain of copy number, more common than loss of copy number (COSMIC Database, v69).
Influenza/human papillomavirus
Note CHD6 has been identified as playing a role in the repression of influenza A infections. It associates with viral ribonuclear proteins in infected cells (Alfonso et al., 2011) . Loss of CHD6 by siRNA silencing results in an increased viral replication, while in lungs of infected mice, CHD6 is degraded upon infection and exposure to the three subunits of the viral polymerase (Alfonso et al., 2013) . Recent reports also indicate that CHD6 interacts with human papillomavirus proteins, binding and repressing the expression of oncogenes (Fertey et al., 2010) . This suggests that CHD6 plays a role in gene suppression and is important in the response to viral infection.
Ataxia
Note Mutations in CHD6 that affect functional subunits are linked to the development of an ataxic phenotype. The deletion of the ATPase region of CHD6 in a mouse model resulted in deficiencies in coordinated movement, which did not progress over time (Lathrop et al., 2010) . Additionally, a recent study utilizing genome wide analysis of genes associate with coordination defects in ADHD identified CHD6 as one of the most relevant target genes (Fliers et al., 2012) .
